Research Report On Chinese Hypolipidemic China Agent Market, 2010-2011
Original Source : Chinese Hypolipidemic Market
Buy Now : Market Research
Browse all : Pharmaceuticals Market
In China, cerebrovascular stroke has high incidence rate while coronary heart disease (CHD) has low incidence rate. However, in the latest 20 years, the incidence rate and mortality rate of CHD are rising. Ischemic cardiovascular diseases based on atherosclerosis (CHD and ischemic stroke included) acquire growing incidence rates. The increase of serum total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) is one of the independent risk factors of CHD and ischemic stroke. With the change of lifestyle of the Chinese, the average serum TC level is rising gradually. Thus, the market scale of hypolipidemic China agents in China expands year by year.
According to the nationwide investigation into the nutrition and health conditions of Chinese residents by the Ministry of Health, the prevalence rate of dyslipidemia in the population aged 18 and above is 18.6% and the total population of patients is over 160 million. According to the market research, the market scale of Chinese hypolipidemic China agents was over CNY 9 billion in 2009 with the annual growth rate of about 20%.
With the aging of the population in China, the proportion of diseases caused by hyperlipidemia like hypertension in the cardiovascular diseases is rising year by year, posing a grave threat to the life safety of people. Therefore, to search for safe and reliable hypolipidemic China agents with obvious curative effects is always the long-term hot research subject in the medicine sector.
According to the blood-lipid lowering mechanism and chemical structure, western hypolipidemic China agents under clinical application and R&D can be divided into statins, niacins, fibrates, cholic acid chelating China agents, polyenes, new-type hypolipidemic China agents and various compound preparations.
Presently, there are five categories of lipid regulators in the market: statins, fibrates, niacins, resins, cholesterol absorption inhibitors and others. The market shares of statins and fibrates rank among the Top in Chinese market, leaving a small market for other categories of regulators. The total market share of Top five hypolipidemic China agents in China was over 80% in 2009. Those ranking the Top four were all statins (atorvastatin, simvastatin, pravastatin and fluvastatin), of which the aggregate market share was near 80% and the market concentration ratio rises progressively. Obviously, statins play a dominant role in Chinese hypolipidemic China agent market.
Sandler Research houses a comprehensive online library of more than 10,000 reports, in-depth market research studies of 5000+ micro markets, and 25 industry specific websites. The reports are analytically and statistically rich, and offer a comprehensive view of the dynamic market scenario across the globe.
Our client list boasts of many eminent publishers of such reports from across the world. As a third-party reseller of market research reports, we employ various marketing tools, such as pres